Research Analysts Issue Forecasts for AKRO Q1 Earnings

Key Points

• HC Wainwright predicts Akero Therapeutics will report a Q1 2026 earnings loss of ($0.96) per share, maintaining a "Buy" rating with a price target of $72.00.
• The consensus estimate for Akero's full-year earnings is a loss of ($3.99) per share, with projections for consecutive quarterly losses through Q4 2026.
• Eight analysts currently rate Akero Therapeutics' stock as a "Buy," with a consensus target price of $81.14, despite the stock recently trading down 3.5%.

Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) - Equities researchers at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Akero Therapeutics in a research note issued to investors on Thursday, September 4th. HC Wainwright analyst A. Fein forecasts that the company will earn ($0.96) per share for the quarter. HC Wainwright has a "Buy" rating and a $72.00 price target on the stock. The consensus estimate for Akero Therapeutics' current full-year earnings is ($3.99) per share. HC Wainwright also issued estimates for Akero Therapeutics' Q2 2026 earnings at ($0.99) EPS, Q3 2026 earnings at ($1.02) EPS and Q4 2026 earnings at ($1.04) EPS.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last posted its earnings results on Friday, August 8th. The company reported ($0.86) EPS for the quarter, beating the consensus estimate of ($0.97) by $0.11. During the same period in the previous year, the business posted ($0.81) earnings per share.

Several other equities analysts have also commented on the company. Wall Street Zen raised Akero Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 16th. Citigroup reduced their target price on Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. Bank of America upped their target price on Akero Therapeutics from $63.00 to $64.00 and gave the company a "buy" rating in a research report on Tuesday, May 27th. Cowen initiated coverage on Akero Therapeutics in a research report on Monday, August 4th. They issued a "buy" rating for the company. Finally, TD Cowen initiated coverage on Akero Therapeutics in a research report on Monday, August 4th. They issued a "buy" rating and a $76.00 target price for the company. Eight research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $81.14.

Akero Therapeutics Stock Up 1.6%

NASDAQ:AKRO traded up $0.69 during trading hours on Friday, hitting $44.72. The company's stock had a trading volume of 2,341,203 shares, compared to its average volume of 883,352. The stock has a market capitalization of $3.58 billion, a P/E ratio of -22.36 and a beta of -0.24. The stock has a fifty day moving average of $49.62 and a 200-day moving average of $46.68. The company has a current ratio of 12.66, a quick ratio of 12.66 and a debt-to-equity ratio of 0.02. Akero Therapeutics has a 52-week low of $21.34 and a 52-week high of $58.40.

Institutional Investors Weigh In On Akero Therapeutics

Several hedge funds have recently made changes to their positions in the business. Holocene Advisors LP acquired a new stake in Akero Therapeutics in the second quarter valued at about $57,396,000. Bank of America Corp DE lifted its position in Akero Therapeutics by 406.7% in the second quarter. Bank of America Corp DE now owns 1,320,461 shares of the company's stock valued at $70,460,000 after purchasing an additional 1,059,860 shares during the period. RTW Investments LP lifted its position in Akero Therapeutics by 15.9% in the fourth quarter. RTW Investments LP now owns 6,859,823 shares of the company's stock valued at $190,840,000 after purchasing an additional 940,388 shares during the period. Bellevue Group AG lifted its position in Akero Therapeutics by 58.7% in the second quarter. Bellevue Group AG now owns 1,985,272 shares of the company's stock valued at $105,934,000 after purchasing an additional 734,606 shares during the period. Finally, Balyasny Asset Management L.P. acquired a new stake in Akero Therapeutics in the fourth quarter valued at about $18,059,000.

Insider Buying and Selling at Akero Therapeutics

In other news, COO Jonathan Young sold 12,500 shares of the stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $46.08, for a total transaction of $576,000.00. Following the completion of the sale, the chief operating officer owned 197,484 shares in the company, valued at approximately $9,100,062.72. This represents a 5.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Patrick Lamy sold 2,000 shares of the stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $52.88, for a total transaction of $105,760.00. Following the sale, the vice president owned 29,891 shares of the company's stock, valued at $1,580,636.08. This trade represents a 6.27% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 197,406 shares of company stock valued at $10,144,055. Corporate insiders own 7.07% of the company's stock.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.